...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of clinical gastroenterology >Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability.
【24h】

Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability.

机译：与消除幽门螺杆菌感染的标准三联疗法相比，为期十天和八天的序贯疗法：疗效和耐受性的随机对照研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Sequential therapy (SQT) is effective in the eradication of Helicobacter pylori and could become an alternative to standard triple therapy (STT). AIM: To compare the efficacy and tolerability of SQT, for either 8 or 10 days, with a 7-day STT. METHODS: A total of 270 naive H. pylori-positive patients were randomized to receive: SQT for 8 days (SQT-8, n=90) or 10 days (SQT-10, n=90) including esomeprazole 20 mg twice daily (bid) associated with amoxicillin 1000 mg bid (early 4 and 5 d, respectively), followed by esomeprazole 20 mg bid associated with clarithromycin 500 mg bid plus tinidazole 500 mg bid (last 4 and 5 d, respectively); STT (n=90) including esomeprazole 20 mg bid plus amoxicillin 1000 mg bid and clarithromycin 500 mg bid for 7 days. Tolerability was assessed by scoring the severity of symptoms. RESULTS: Eradication rates after SQT-8 and SQT-10 were higher than that of after STT at both intention-to-treat (83% and 86% vs. 66%, P<0.02) and per-protocol analysis (90% and 88% vs. 75%, P<0.05), whereas no difference was found between the 2 SQTs. CONCLUSIONS: This study shows that SQT, for 8 or 10 days, is well tolerated and highly effective in H. pylori eradication and could represent a valid alternative to STT. Further studies, with more power, on larger populations and from other countries are necessary to validate the present findings.
机译：背景：序贯疗法（SQT）在根除幽门螺杆菌方面有效，并且可能成为标准三联疗法（STT）的替代方法。目的：比较SQT在7天STT下8天或10天的疗效和耐受性。方法：总共270例未接受治疗的幽门螺杆菌阳性患者随机接受：SQT连续8天（SQT-8，n = 90）或10天（SQT-10，n = 90），其中包括每天两次两次的艾美拉唑20 mg（出价）与阿莫西林1000毫克出价（分别为4天和5 d）相关，随后是埃索美拉唑20毫克出价与克拉霉素500毫克出价和替硝唑500毫克出价（分别为最后4天和5 d）相关; STT（n = 90）包括7天的埃索美拉唑20毫克出价，阿莫西林1000毫克出价和克拉霉素500毫克出价。通过对症状的严重程度评分来评估耐受性。结果：在意向性治疗（分别为83％和86％对66％，P <0.02）和按方案分析（分别为90％和88％和75％，P <0.05），而两个SQT之间没有发现差异。结论：这项研究表明，SQT在8或10天中具有良好的耐受性，并且在根除幽门螺杆菌方面非常有效，并且可以代表STT的有效替代方案。有必要对更大范围的人口和其他国家进行更强大的研究，以验证目前的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号